Steroid-induced iatrogenic glaucoma

Ophthalmic Research

Volumn 47, Issue 2, 2012, Pages 66-80

  Razeghinejad, M Reza ^a,b   Katz, L Jay ^b  

^a SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b WILLS EYE HOSPITAL   (United States)

Author keywords

Glaucoma; Intravitreal drug delivery; Steroid induced ocular hypertension

Indexed keywords

ACETAZOLAMIDE; ANECORTAVE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRIMONIDINE; DEXAMETHASONE; FLUOROMETHOLONE; HYDROCORTISONE; MEDRYSONE; MYOCILIN; PREDNISOLONE; STEROID; TRIAMCINOLONE;

DIABETES MELLITUS; DRUG WITHDRAWAL; GENE EXPRESSION; GENETIC SUSCEPTIBILITY; GLAUCOMA; GLAUCOMA DRAINAGE IMPLANT; HIGH RISK PATIENT; HUMAN; IATROGENIC DISEASE; IATROGENIC GLAUCOMA; INTRAOCULAR PRESSURE; OPEN ANGLE GLAUCOMA; PRIORITY JOURNAL; REVIEW; RISK FACTOR; TRABECULAR MESHWORK; TRABECULECTOMY; TRABECULOPLASTY; VITRECTOMY;

AGE FACTORS; GENETIC PREDISPOSITION TO DISEASE; GLAUCOMA; HUMANS; INTRAOCULAR PRESSURE; OCULAR HYPERTENSION; RISK FACTORS; SEX FACTORS; STEROIDS; TRABECULAR MESHWORK;

EID: 79960273707     PISSN: 00303747     EISSN: 14230259     Source Type: Journal    
DOI: 10.1159/000328630     Document Type: Review

References (73)

1. Woods AC: Clinical and experimental observation on the use of ACTH and cortisone in ocular inflammatory disease. Trans Am Ophthalmol Soc 1950;48:259-296.
2. Covell LL: Glaucoma induced by systemic steroid therapy. Am J Ophthalmol 1958;45:108-109.
3. Goldmann H: Cortisone glaucoma. Arch Ophthalmol 1962;68:621-626.
4. Armaly MF, Becker B: Intraocular pressure response to topical corticosteroids. Fed Proc 1965;24:1274-1278.
5. Becker B: Intraocular pressure response to topical corticosteroids. Invest Ophthalmol 1965;4:198-205.
6. Urban RC Jr, Dreyer EB: Corticosteroid-induced glaucoma. Int Ophthalmol Clin 1993;33:135-139.
7. Shaikh NM, Shaikh S, Singh K, Manche E: Progression to end-stage glaucoma after laser in situ keratomileusis. J Cataract Refract Surg 2002;28:356-359.
8. Morales J, Good D: Permanent glaucomatous visual loss after photorefractive keratectomy. J Cataract Refract Surg 1998;24:715-718.
9. Samuelson TW: Refractive surgery in glaucoma. Curr Opin Ophthalmol 2004;15:112-118.
10. Hamilton DR, Manche EE, Rich LF, Maloney RK: Steroid-induced glaucoma after laser in situ keratomileusis associated with interface fluid. Ophthalmology 2002;109:659-665.
11. Lau LI, Chen KC, Lee FL, Chen SJ, Ko YC, Liu CJ, Hsu WM: Intraocular pressure elevation after intravitreal triamcinolone acetonide injection in a Chinese population. Am J Ophthalmol 2008;146:573-578.
12. Rhee DJ, Peck RE, Belmont J, Martidis A, Liu M, Chang J, Fontanarosa J, Moster MR: Intraocular pressure alterations following intravitreal triamcinolone acetonide. Br J Ophthalmol 2006;90:999-1003.
13. Roth DB, Verma V, Realini T, Prenner JL, Feuer WJ, Fechtner RD: Long-term incidence and timing of intraocular hypertension after intravitreal triamcinolone acetonide injection. Ophthalmology 2009;116:455-460.
14. Vasconcellos JP, Melo MB, Costa VP, Tsukumo DM, Basseres DS, Bordin S, Saad ST, Costa FF: Novel mutation in the MYOC gene in primary open glaucoma patients. J Med Genet 2000;37:301-303.
15. Im L, Allingham RR, Singh I, Stinnett S, Fekrat S: A prospective study of early intraocular pressure changes after a single intravitreal triamcinolone injection. J Glaucoma 2008;17:128-132.
16. Yamamoto Y, Komatsu T, Koura Y, Nishino K, Fukushima A, Ueno H: Intraocular pressure elevation after intravitreal or posterior sub-Tenon triamcinolone acetonide injection. Can J Ophthalmol 2008;43:42-47.
17. Baath J, Ells AL, Crichton A, Kherani A, Williams RG: Safety profile of intravitreal triamcinolone acetonide. J Ocul Pharmacol Ther 2007;23:304-310.
18. Kramar M, Vu L, Whitson JT, He YG: The effect of intravitreal triamcinolone on intraocular pressure. Curr Med Res Opin 2007;23:1253-1258.
19. Gregori NZ, Rosenfeld PJ, Puliafito CA, Flynn HW Jr, Lee JE, Mavrofrides EC, Smiddy WE, Murray TG, Berrocal AM, Scott IU, Gregori G: One-year safety and efficacy of intravitreal triamcinolone acetonide for the management of macular edema secondary to central retinal vein occlusion. Retina 2006;26:889-895.
20. Konstantopoulos A, Williams CP, Newsom RS, Luff AJ: Ocular morbidity associated with intravitreal triamcinolone acetonide. Eye (Lond) 2007;21:317-320.
21. Park HY, Yi K, Kim HK: Intraocular pressure elevation after intravitreal triamcinolone acetonide injection. Korean J Ophthalmol 2005;19:122-127.
22. Smithen LM, Ober MD, Maranan L, Spaide RF: Intravitreal triamcinolone acetonide and intraocular pressure. Am J Ophthalmol 2004;138:740-743.
23. Bakri SJ, Beer PM: The effect of intravitre - al triamcinolone acetonide on intraocular pressure. Ophthalmic Surg Lasers Imaging 2003;34:386-390.
24. Jonas JB, Degenring RF, Kreissig I, Akkoyun I, Kamppeter BA: Intraocular pressure elevation after intravitreal triamcinolone acetonide injection. Ophthalmology 2005;112:593-598.
25. Vasconcelos-Santos DV, Nehemy PG, Schachat AP, Nehemy MB: Secondary ocular hypertension after intravitreal injec - tion of 4 mg of triamcinolone acetonide: incidence and risk factors. Retina 2008;28:573-580.
26. Francois J: Corticosteroid glaucoma. Ann Ophthalmol 1977;9:1075-1080.
27. Bernstein HN, Schwartz B: Effects of longterm systemic steroids on ocular pressure and tonographic values. Arch Ophthalmol 1962;68:742-753.
28. Armaly MF: Effect of corticosteroids on intraocular pressure and fluid dynamics. I. The effect of dexamethasone in the normal eye. Arch Ophthalmol 1963;70:482-491.
29. Armaly MF: Effect of corticosteroids on intraocular pressure and fluid dynamics. II. The effect of dexamethasone in the glaucomatous eye. Arch Ophthalmol 1963;70:492-499.
30. Becker B, Mills DW: Corticosteroids and intraocular pressure. Arch Ophthalmol 1963;70:500-507.
31. Carnahan MC, Goldstein DA: Ocular complications of topical, peri-ocular, and systemic corticosteroids. Curr Opin Ophthalmol 2000;11:478-483.
32. American Academy of Ophthalmology: Basic and Clinical Science Course, Section 2: Fundamentals and Principles of Ophthalmology. San Francisco, American Academy of Ophthalmology, 2008, p 419.
33. Tripathi RC, Kirschner BS, Kipp M, Tripathi BJ, Slotwiner D, Borisuth NS, Karrison T, Ernest JT: Corticosteroid treatment for inflammatory bowel disease in pediatric patients increases intraocular pressure. Gastroenterology 1992;102:1957-1961.
34. Herschler J: Intractable intraocular hypertension induced by repository triamcinolone acetonide. Am J Ophthalmol 1972;74:501-504.
35. Helm CJ, Holland GN: The effects of posterior subTenon injection of triamcinolone acetonide in patients with intermediate uveitis. Am J Ophthalmol 1995;120:55-64.
36. Kalina RE: Increased intraocular pressure following subconjunctival corticosteroid administration. Arch Ophthalmol 1969;81:788-790.
37. Hirooka K, Shiraga F, Tanaka S, Baba T, Mandai H: Risk factors for elevated intraocular pressure after trans-Tenon retrobulbar injections of triamcinolone. Jpn J Ophthalmol 2006;50:235-238.
38. Jones R, 3rd, Rhee DJ: Corticosteroid-induced ocular hypertension and glaucoma: a brief review and update of the literature. Curr Opin Ophthalmol 2006;17:163-167.
39. Singh IP, Ahmad SI, Yeh D, Challa P, Herndon LW, Allingham RR, Lee PP: Early rapid rise in intraocular pressure after intravitreal triamcinolone acetonide injection. Am J Ophthalmol 2004;138:286-287.
40. Vedantham V: Intraocular pressure rise after intravitreal triamcinolone. Am J Ophthalmol 2005;139:575; author reply 576.
41. Herschler J: Increased intraocular pressure induced by repository corticosteroids. Am J Ophthalmol 1976;82:90-93.
42. Kalina PH, Erie JC, Rosenbaum L: Biochemical quantification of triamcinolone in subconjunctival depots. Arch Ophthalmol 1995;113:867-869.
43. Goldstein DA, Fiscella RG, Tessler HH: Biochemical quantification of triamcinolone in subconjunctival depots. Arch Ophthalmol 1996;114:363-364.
44. Davies TG: Tonographic survey of the close relatives of patients with chronic simple glaucoma. Br J Ophthalmol 1968;52:32-39.
45. Gaston H, Absolon MJ, Thurtle OA, Sattar MA: Steroid responsiveness in connective tissue diseases. Br J Ophthalmol 1983;67:487-490.
46. Spaeth GL, Rodrigues MM, Weinreb S: Steroidinduced glaucoma: A. Persistent elevation of intraocular pressure. B. Histopathological aspects. Trans Am Ophthalmol Soc 1977;75:353-381.
47. Podos SM, Becker B, Morton WR: High myopia and primary open-angle glaucoma. Am J Ophthalmol 1966;62:1038-1043.
48. Becker B: Diabetes mellitus and primary open-angle glaucoma. The XXVII Edward Jackson Memorial Lecture. Am J Ophthalmol 1971;71:1-16.
49. Spaeth GL: Traumatic hyphema, angle recession, dexamethasone hypertension, and glaucoma. Arch Ophthalmol 1967;78:714-721.
50. Becker B, Mills DW: Corticosteroid and intraocular pressure. Arch Ophthalmol 1963;70:500-507.
51. Becker B, Mills DW: Elevated intraocular pressure following corticosteroid eye drops. JAMA 1963;185:884-886.
52. François J, Heintz-De Bree C, Tripathi RC: The cortisone test and heredity of early open-angle glaucoma (in French). Bull Soc Belge Ophtalmol 1965;141:576-581.
53. Becker B: The effect of topical corticosteroids in secondary glaucoma. Arch Ophthalmol 1964;72:769-771.
54. Reichle ML: Complications of intravitreal steroid injections. Optometry 2005;76:450-460.
55. Oliver A, Gao H, Wu Dunn D, Peracha MO, Cantor LB: Intravitreal triamcinolone injection in patients with surgically control - led glaucoma. Arch Ophthalmol 2006;124:1788-1790.
56. Kitazawa Y, Horie T: The prognosis of corticosteroidresponsive individuals. Arch Ophthalmol 1981;99:819-823.
57. Kass MA, Kolker AE, Becker B: Chronic topical corticosteroid use simulating congenital glaucoma. J Pediatr 1972;81:1175-1177.
58. Ohji M, Kinoshita S, Ohmi E, Kuwayama Y: Marked intraocular pressure response to instillation of corticosteroids in children. Am J Ophthalmol 1991;112:450-454.
59. Lam DS, Fan DS, Ng JS, Yu CB, Wong CY, Cheung AY: Ocular hypertensive and antiinflammatory responses to different dosages of topical dexamethasone in children: a randomized trial. Clin Experiment Ophthalmol 2005;33:252-258.
60. Yamashita T, Kodama Y, Tanaka M, Yamakiri K, Kawano Y, Sakamoto T: Steroid-induced glaucoma in children with acute lymphoblastic leukemia: a possible complication. J Glaucoma 2010;19:188-190.
61. Kwok AK, Lam DS, Ng JS, Fan DS, Chew SJ, Tso MO: Ocular-hypertensive response to topical steroids in children. Ophthalmology 1997;104:2112-2116.
62. Becker B, Bresnick G, Chevrette L, Kolker AE, Oaks MC, Cibis A: Intraocular pressure and its response to topical corticosteroids in diabetes. Arch Ophthalmol 1966;76:477-483.
63. Armaly MF: Statistical attributes of steroid hypertensive response in the clinically normal eye. I. The demonstration of three levels of response. Invest Ophthalmol 1965;4:187-197.
64. Becker B, Hahn KA: Topical corticosteroids and heredity in primary open-angle glaucoma. Am J Ophthalmol 1964;57:543-551.
65. Mueller AJ, Jian G, Banker AS, Rahhal FM, Capparelli E, Freeman WR: The effect of deep posterior subTenon injection of corticosteroids on intraocular pressure. Am J Ophthalmol 1998;125:158-163.
66. Schwartz JT, Reuling FH, Feinleib M, Garrison RJ, Collie DJ: Twin study on ocular pressure following topically applied dexamethasone. II. Inheritance of variation in pressure response. Arch Ophthalmol 1973;90:281-286.
67. Alward WL: The genetics of open-angle glaucoma: The story of GLC1A and myocilin. Eye (Lond) 2000;14:429-436.
68. Polansky JR, Nguyen TD: The TIGR gene, pathogenic mechanisms, and other recent advances in glaucoma genetics. Curr Opin Ophthalmol 1998;9:15-23.
69. Lo WR, Rowlette LL, Caballero M, Yang P, Hernandez MR, Borras T: Tissue differential microarray analysis of dexamethasone induction reveals potential mechanisms of steroid glaucoma. Invest Ophthalmol Vis Sci 2003;44:473-485.
70. Liu Y, Vollrath D: Reversal of mutant myocilin non-secretion and cell killing: implications for glaucoma. Hum Mol Genet 2004;13:1193-1204.
71. Zillig M, Wurm A, Grehn FJ, Russell P, Tamm ER: Overexpression and properties of wild-type and Tyr437His mutated myocilin in the eyes of transgenic mice. Invest Ophthalmol Vis Sci 2005;46:223-234.
72. Gould DB, Miceli-Libby L, Savinova OV, Torrado M, Tomarev SI, Smith RS, John SW: Genetically increasing Myoc expression supports a necessary pathologic role of abnormal proteins in glaucoma. Mol Cell Biol 2004;24:9019-9025.
73. Fingert JH, Clark AF, Craig JE, Alward WL, Snibson GR, McLaughlin M, Tuttle L, Mackey DA, Sheffield VC, Stone EM: Evaluation of the myocilin (MYOC) glaucoma gene in monkey and human steroid-induced ocular hypertension. Invest Ophthalmol Vis Sci 2001;42:145-152.